Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology

Lupenone has been reported to possess numerous medicinal values and gives a positive antidiabetic effect. But the mechanism of preventing and treating type 1 diabetes has not been elucidated in type 1 diabetic rats. This study investigated the effects and mechanism of action of lupenone in preventin...

Full description

Bibliographic Details
Main Authors: Wu, Hongmei, Huang, Xulong, Xu, Feng, Li, Xiaofen, Liang, Yuqing, Yang, Liubo, Wang, Xiangpei
Format: Article
Language:English
Published: Penerbit Universiti Kebangsaan Malaysia 2023
Online Access:http://journalarticle.ukm.my/22801/
http://journalarticle.ukm.my/22801/1/SEN%2015.pdf
_version_ 1848815688350695424
author Wu, Hongmei
Huang, Xulong
Xu, Feng
Li, Xiaofen
Liang, Yuqing
Yang, Liubo
Wang, Xiangpei
author_facet Wu, Hongmei
Huang, Xulong
Xu, Feng
Li, Xiaofen
Liang, Yuqing
Yang, Liubo
Wang, Xiangpei
author_sort Wu, Hongmei
building UKM Institutional Repository
collection Online Access
description Lupenone has been reported to possess numerous medicinal values and gives a positive antidiabetic effect. But the mechanism of preventing and treating type 1 diabetes has not been elucidated in type 1 diabetic rats. This study investigated the effects and mechanism of action of lupenone in preventing and treating type 1 diabetes by network pharmacology and diabetic rats. The blood glucose, glycosylated hemoglobin (HbA1c), insulin, and inflammatory factors in the pancreas of rats with type 1 diabetes were measured, and histopathological changes were observed after treatment with lupenone. The pharmacological network of ‘component-target-disease’ was constructed on diabetic rats. Gene function enrichment, the Kyoto Encyclopedia of Genes and Genomes pathway analysis, and molecular docking were performed. The results showed that lupenone can decrease fasting blood glucose and HbA1c levels, increase insulin content and interleukin (IL)-4, IL-10, and decrease IL-6, transforming growth factor β and tumor necrosis factor α levels in the pancreas. Furthermore, ten targets were identified, and 50 signal pathways closely related to type 1 diabetes and inflammation were screened by network pharmacology, including insulin resistance, type II diabetes, type I diabetes, insulin signal pathway, mitogen activated protein kinase (MAPK) signal pathway, and tumor necrosis factor (TNF) signal pathway. The docking affinity of potential targets and lupenone were between -3.3 and -9.8, among which caspase-3 (CASP3), cyclin-dependent kinase 4 (CDK4), inhibitor of kappaB kinase beta (IKBKB), transforming growth factor beta-1 (TGFB1), and TNF had high binding abilities. Thus, lupenone has the potential to be developed as a new drug for treating type 1 diabetes.
first_indexed 2025-11-15T00:53:57Z
format Article
id oai:generic.eprints.org:22801
institution Universiti Kebangasaan Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T00:53:57Z
publishDate 2023
publisher Penerbit Universiti Kebangsaan Malaysia
recordtype eprints
repository_type Digital Repository
spelling oai:generic.eprints.org:228012024-01-04T07:12:38Z http://journalarticle.ukm.my/22801/ Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology Wu, Hongmei Huang, Xulong Xu, Feng Li, Xiaofen Liang, Yuqing Yang, Liubo Wang, Xiangpei Lupenone has been reported to possess numerous medicinal values and gives a positive antidiabetic effect. But the mechanism of preventing and treating type 1 diabetes has not been elucidated in type 1 diabetic rats. This study investigated the effects and mechanism of action of lupenone in preventing and treating type 1 diabetes by network pharmacology and diabetic rats. The blood glucose, glycosylated hemoglobin (HbA1c), insulin, and inflammatory factors in the pancreas of rats with type 1 diabetes were measured, and histopathological changes were observed after treatment with lupenone. The pharmacological network of ‘component-target-disease’ was constructed on diabetic rats. Gene function enrichment, the Kyoto Encyclopedia of Genes and Genomes pathway analysis, and molecular docking were performed. The results showed that lupenone can decrease fasting blood glucose and HbA1c levels, increase insulin content and interleukin (IL)-4, IL-10, and decrease IL-6, transforming growth factor β and tumor necrosis factor α levels in the pancreas. Furthermore, ten targets were identified, and 50 signal pathways closely related to type 1 diabetes and inflammation were screened by network pharmacology, including insulin resistance, type II diabetes, type I diabetes, insulin signal pathway, mitogen activated protein kinase (MAPK) signal pathway, and tumor necrosis factor (TNF) signal pathway. The docking affinity of potential targets and lupenone were between -3.3 and -9.8, among which caspase-3 (CASP3), cyclin-dependent kinase 4 (CDK4), inhibitor of kappaB kinase beta (IKBKB), transforming growth factor beta-1 (TGFB1), and TNF had high binding abilities. Thus, lupenone has the potential to be developed as a new drug for treating type 1 diabetes. Penerbit Universiti Kebangsaan Malaysia 2023 Article PeerReviewed application/pdf en http://journalarticle.ukm.my/22801/1/SEN%2015.pdf Wu, Hongmei and Huang, Xulong and Xu, Feng and Li, Xiaofen and Liang, Yuqing and Yang, Liubo and Wang, Xiangpei (2023) Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology. Sains Malaysiana, 52 (6). pp. 1795-1810. ISSN 0126-6039 https://www.ukm.my/jsm/english_journals/vol52num6_2023/contentsVol52num6_2023.html
spellingShingle Wu, Hongmei
Huang, Xulong
Xu, Feng
Li, Xiaofen
Liang, Yuqing
Yang, Liubo
Wang, Xiangpei
Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title_full Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title_fullStr Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title_full_unstemmed Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title_short Exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
title_sort exploring the antidiabetic effect of lupenone in rats with type 1 diabetes and its underlying mechanism based on network pharmacology
url http://journalarticle.ukm.my/22801/
http://journalarticle.ukm.my/22801/
http://journalarticle.ukm.my/22801/1/SEN%2015.pdf